Welltower (NYSE: WELL) — 2Q26 Earnings Preview

Date clarification: Today is Monday, July 27, 2026. The prompt describes July 27 as “tomorrow”; I have treated this as a pre-results preview for the stated 2Q26 earnings event. No 2Q26 earnings release or transcript was available in the document database at the time of this analysis.

Investment view: execution must remain exceptional

Welltower enters 2Q with operating momentum, an enlarged seniors-housing platform, and substantial capital-market flexibility. The core question is no longer whether the portfolio can grow—it clearly has been—but whether SHOP/Senior Housing Operating (SHO) growth, occupancy gains, margin expansion, and capital deployment can continue at a rate sufficient to support a demanding share price.

The setup is constructive operationally:

But expectations are elevated. WELL closed at $252.11 on July 24, up about 36% from December 31, 2025 and 28% from March 31. At that price, the stock trades at roughly 40x the midpoint of current 2026 normalized-FFO guidance. The market is therefore likely to demand continued upside—not simply a clean quarter.

What matters most in 2Q

1. SHO occupancy, pricing, and flow-through

This remains the central driver. Management’s 2026 midpoint assumptions call for:

2026 guide component Midpoint assumption
Total same-store NOI growth 14.1%
SHO same-store NOI growth 19.0%
SHO revenue growth 9.2%
SHO occupancy growth 350 bps
SHO RevPOR growth 5.0%
SHO ExpPOR growth ~1.3%

The key issue for 2Q is whether WELL can sustain—or improve upon—the 1Q formula: healthy occupancy growth, durable rate growth, and unusually restrained expense growth.

In 1Q, SHO operating leverage was striking: same-store NOI margin expanded 320 bps to 30.9%, while management cited 64% flow-through. Labor represents roughly 60% of SHO expenses, so investors should focus on compensation per occupied room, staffing needs as communities fill, and whether cost discipline remains intact during the summer leasing season.

Bullish read-through: occupancy stays near the guided pace, RevPOR remains around or above 5%, and expenses grow materially below revenue.

Bearish read-through: occupancy gains decelerate, higher occupancy requires incremental labor faster than expected, or pricing becomes more dependent on increases to existing residents rather than new-lease “street” rates.

2. The full-quarter contribution from Amica

The acquisition of Amica Senior Lifestyles closed on April 1, 2026, meaning 2Q should be the first quarter with a full contribution. WELL acquired 34 Canadian senior-housing communities plus interests in four unconsolidated properties for approximately C$4.0 billion, assumed C$567 million of secured debt, and also entered forward-purchase commitments for five development properties.

This is important for three reasons:

  1. It increases exposure to a high-quality, private-pay Canadian senior-housing platform.
  2. It should add to consolidated revenue, NOI, and FFO in 2Q.
  3. It tests WELL’s ability to integrate a major platform while retaining the operating and cultural advantages that underpin its strategy.

Investors should look for commentary on Amica’s initial occupancy, rate, margin, and integration trends—not merely its aggregate earnings contribution.

3. Guidance: can WELL raise again?

Management raised the annual normalized-FFO midpoint by $0.11 after 1Q. The drivers were:

The existing annual midpoint implies that the remaining three quarters collectively need to average roughly $1.58–$1.63 per share of normalized FFO, versus $1.47 in 1Q. That is feasible given full-quarter acquisition contributions, continuing occupancy gains, and the capital pipeline—but it also makes the guide more sensitive to operating or financing slippage.

A second raise would be the clearest positive catalyst. More likely, the debate will be whether management reaffirms with confidence or preserves upside through a conservative guide.

Capital allocation is the other major earnings variable

WELL is actively transforming its asset mix away from lower-growth medical office and toward senior housing. That strategy has supported growth but adds complexity around timing, funding, dilution, and disposition proceeds.

Recent capital activity to assess

The financing is a positive signal of capital-market access and provides flexibility for the investment pipeline. However, investors will want clarity on the uses of proceeds, the path for upcoming maturities, and whether capital deployment remains accretive on a per-share basis after equity issuance and funding costs.

Dilution deserves close attention

WELL issued 7.7 million shares through its ATM program in 1Q at an average price of $202.68, raising roughly $1.54 billion net. It also sold another 1.24 million shares under the ATM in April.

The company has credibly used its equity currency to finance a large portfolio repositioning while reducing leverage. Still, with the stock now materially higher, investors should watch:

The right outcome is continued asset growth and per-share FFO accretion—not simply a larger enterprise.

Balance sheet: strong, but active

At March 31, WELL reported:

WELL subsequently repaid a $700 million senior-note maturity in April using free cash flow. The July Canadian-dollar notes add funding capacity, although the company remains active in both Canadian and U.K. markets and therefore carries meaningful foreign-currency and capital-markets exposure.

For 2Q, the preferred outcome is a balance sheet that remains comfortably positioned while funding acquisitions primarily through a mix of disposition proceeds, retained cash flow, assumed debt, and selective equity—not a material step-up in leverage.

Portfolio mix and strategic execution

The company’s structural story is increasingly straightforward: more seniors housing, less outpatient medical office, and greater use of its operating/data platforms.

At 1Q:

The near-term earnings relevance of data licensing and fund-management fees is limited relative to core SHO NOI. Their strategic relevance is more meaningful: they could add incremental fee income, reinforce WELL’s sourcing advantage, and potentially improve the velocity of capital allocation. For now, investors should avoid assigning too much value until recurring revenue, margins, and contract economics become more tangible.

Key risks into the print

  1. High valuation and crowded expectations. At roughly 40x 2026 guidance midpoint, an in-line result without a stronger outlook may not be enough.
  2. Occupancy and labor normalization. The current SHO growth profile benefits from lease-up, pricing, and operating leverage. Any slowdown in occupancy or acceleration in labor expense would pressure the thesis.
  3. Acquisition/integration risk. Amica and other recent investments must perform operationally, not just add scale.
  4. Capital-allocation and dilution risk. Large investment volumes can obscure weaker per-share economics if funded too heavily by equity.
  5. Disposition timing and reinvestment risk. WELL is recycling capital out of outpatient medical and other slower-growth assets; delayed sales or less favorable redeployment could impair guidance.
  6. Foreign-currency and interest-rate exposure. The company has substantial U.K. and Canadian operations and finances in multiple currencies.

What would change the narrative?

Positive surprise

Disappointing outcome

Bottom line

WELL’s 2Q report should be viewed primarily as a test of the durability of its senior-housing operating model. The most important metrics are SHO occupancy, RevPOR, expense growth, NOI margin, and the full-quarter contribution from Amica. Capital allocation and balance-sheet discipline are close seconds.

The company has the ingredients for another strong report: favorable senior-housing fundamentals, substantial operating leverage, a recently expanded portfolio, and ample liquidity. But following a roughly 36% year-to-date share-price gain through July 24, the hurdle is high. Investors are likely to reward evidence that the 20%-plus SHO-NOI growth engine can persist and that investment activity is still translating into superior per-share growth.

Research basis